PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
about
Checkpoint Inhibitors and Their Application in Breast CancerThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsChallenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerPrognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.Prognostic value of PDL1 expression in pancreatic cancerPlacental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report.Mechanism of immune evasion in breast cancer.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.XPO1, therapeutic … and prognostic target in sarcomas.Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.The Role of Immune Escape and Immune Cell Infiltration in Breast CancerALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation
P2860
Q26745442-06233084-9EBA-499C-BF54-DF6D0BF388C2Q26766066-0E509BF9-9DD3-4612-A050-1B3D59BF83F2Q28075322-3CACB52D-E8A2-4E4C-8543-8DC33659ACCBQ33760216-4EF21DA5-C468-48C9-BE2F-9819968A1EF1Q36030084-41E47E95-B3F2-41E4-816E-B6AE3A3B3737Q37687595-033CF50B-D4A8-4BFA-AEA6-E113649CFB5EQ37696391-D37B347F-6579-448A-9AA0-833D64B1731CQ37712385-BEEFD9D4-2A18-4506-BBCA-512DBD2C745EQ38629357-A76EB232-8BF9-4117-9A14-AFCE1D4C8B08Q38683638-58A79310-725F-4F2F-8D1C-481A6E720582Q39102913-5A68285F-B113-412A-8607-F4AA39F0E3F9Q39641921-A46E2388-C030-49F2-B48C-AF7E49E5FB79Q40436041-2DC42107-E73A-40FB-B34A-3212ABB7DB0AQ40560246-2CF5863A-CE8B-4665-B2DD-87AF1C1499AAQ42395964-98A5A2FD-0EFC-44AF-9961-7BB6FB586495Q42504152-7CCEE91E-A328-4445-ACE6-F812696F2DE9Q42700740-93A71C16-309E-417A-BB8A-E4BDEC9FA517Q45916506-23DA1A7F-DD56-4826-8DB5-5F50BB6AE8D0Q47576215-BFCFAD74-9190-4CF9-8207-65813D13EC47Q52733772-CABD77DC-5B8C-42F5-A359-8BBDEC7A6605Q54981008-591745C0-6F2E-4325-9D83-8C81BE074586Q57114285-86CF1E21-F3E8-42F2-9E26-A6FBF0884659Q57950156-50E597D8-6DC1-4985-AF04-F02454D77B56
P2860
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PDL1 expression in inflammator ...... ical response to chemotherapy.
@ast
PDL1 expression in inflammator ...... ical response to chemotherapy.
@en
type
label
PDL1 expression in inflammator ...... ical response to chemotherapy.
@ast
PDL1 expression in inflammator ...... ical response to chemotherapy.
@en
prefLabel
PDL1 expression in inflammator ...... ical response to chemotherapy.
@ast
PDL1 expression in inflammator ...... ical response to chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
PDL1 expression in inflammator ...... ical response to chemotherapy.
@en
P2093
Cécile Colpaert
Daniel Birnbaum
Emilie Mamessier
François Bertucci
Maxime Parizel
Pascal Finetti
Patrice Viens
Steven van Laere
P2860
P304
13506-13519
P356
10.18632/ONCOTARGET.3642
P407
P577
2015-05-01T00:00:00Z